S1PR1‐Overexpressing Membrane‐Coated Nanoparticles Inhibit Dedifferentiation Progression for the Treatment of Anaplastic Thyroid Carcinoma by Targeting the ACER3/SPHK1/S1P Pathway
Advanced Healthcare Materials · 2026-06 · 15 (24)
DOI: 10.1002/adhm.202505384 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 11.05.2026. Verfasst von Yang Bai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Provincial Clinical Research Center For Head & Neck Cancer, Hangzhou, China. Hauptthemen laut MEDLINE: Nanoparticles, Phosphotransferases (Alcohol Group Acceptor), Thyroid Carcinoma, Anaplastic, Sphingosine-1-Phosphate Receptors. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province, China Postdoctoral Science Foundation, Medical and Health Science and Technology Plan Project of Zhejiang Province.
Abstract (Originalsprache)
Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy with a poor prognosis, characterized by dedifferentiation and aberrant angiogenesis. Through integrated analysis of TCGA and GEO transcriptomic data and single‐cell RNA sequencing, this study identified significant enrichment of angiogenesis‐related genes (ARGs), particularly sphingosine kinase 1 (SPHK1), in malignant cell subpopulations of ATC. Functional investigations revealed that alkaline ceramidase 3 (ACER3) cooperates with SPHK1 within the sphingolipid metabolic pathway to promote ATC progression. The SPHK1‐specific inhibitor PF543 suppresses the activity of this key protein, thereby exhibiting potential therapeutic effects. To address the poor aqueous solubility and limited targeting ability of PF543, we constructed biomimetic nanoparticles (CMOE@PLGA@PF543) coated with S1PR1‐overexpressing cancer cell membranes (CMOE), enabling tumor‐specific targeting through the sphingosine‐1‐phosphate (S1P) and sphingosine‐1‐phosphate receptor 1 (S1PR1) ligand‐receptor interaction. In vitro, PF543 downregulated SPHK1 expression and induced apoptosis in ATC cells. In vivo, CMOE@PLGA@PF543 exhibited enhanced tumor‐targeting accumulation, excellent biosafety, and potent inhibition of tumor growth by suppressing the ACER3/SPHK1/S1P axis. These findings reveal a novel molecular mechanism driving ATC progression and offer a targeted nanotherapeutic strategy with strong potential for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhejiang Provincial Clinical Research Center For Head & Neck Cancer, Hangzhou, China.
- Zhejiang Key Laboratory of Precision Medicine Research on Head & Neck Cancer, Hangzhou, China.
- School of Public Health, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Center For Plastic & Reconstructive Surgery, Department of Stomatology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
- Department of General Surgery, Jinhua Central Hospital, Teaching Hospital of Mathematical Medicine College, Zhejiang Normal University, Zhejiang, China.
- Department of Thyroid Head and Neck Surgery, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
ORCID-Profile: Minghua Ge
Förderung
- Natural Science Foundation of Zhejiang Province
- China Postdoctoral Science Foundation
- Medical and Health Science and Technology Plan Project of Zhejiang Province
- Medical and Health Science Program of Zhejiang Province
- Basic Scientific Research Funds of Department of Education of Zhejiang Province
- Zhejiang Provincial Science and Technology Program
- Basal Research Fund of Hangzhou medical college
Zitieren
APA
Bai, Y., Chen, J., Lin, H., Ma, W., Zhu, M., Zhang, Y., Duan, Y., Xu, J., & Ge, M. (2026). S1PR1‐Overexpressing Membrane‐Coated Nanoparticles Inhibit Dedifferentiation Progression for the Treatment of Anaplastic Thyroid Carcinoma by Targeting the ACER3/SPHK1/S1P Pathway. Advanced Healthcare Materials, 15(24). https://doi.org/10.1002/adhm.202505384
Vancouver
Bai Y, Chen J, Lin H, Ma W, Zhu M, Zhang Y, et al. S1PR1‐Overexpressing Membrane‐Coated Nanoparticles Inhibit Dedifferentiation Progression for the Treatment of Anaplastic Thyroid Carcinoma by Targeting the ACER3/SPHK1/S1P Pathway. Advanced Healthcare Materials. 2026;15(24). doi:10.1002/adhm.202505384
BibTeX
@article{Bai2026,
author = {Bai, Yang and Chen, Jiaqi and Lin, Haiping and Ma, Weike and Zhu, Mengting and Zhang, Yuxiang and Duan, Yanting and Xu, Jiajie and Ge, Minghua},
title = {S1PR1‐Overexpressing Membrane‐Coated Nanoparticles Inhibit Dedifferentiation Progression for the Treatment of Anaplastic Thyroid Carcinoma by Targeting the ACER3/SPHK1/S1P Pathway},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {24},
doi = {10.1002/adhm.202505384}
}
EUVIMED